ex vivo expanded human autologous polyclonal regulatory t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2010 (NCT01210664)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- regulatory t cellsSupplementation
regulatory t cells supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ex vivo expanded human autologous polyclonal regulatory t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06708780 | Phase 1 | Apr 12, 2023 | Chinese Academy of Medical Sciences, Nanjing University |
| NCT02428309 | Phase 1 | Jul 1, 2015 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco |
| NCT01210664 | Phase 1 | Nov 1, 2010 | Juvenile Diabetes Research Foundation, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco, Yale University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 1 | 1 | 2010 |
| University of California, San Francisco | Academic/Hospital | 2 | 1 | 1 | 2010 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Juvenile Diabetes Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2010 |
6 organizations
Page 1 / 1